|
AzurRx BioPharma Announces Closing of $6.9 Million Private Placement
|
13 Jan, 2020 |
|
AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco
|
09 Jan, 2020 |
|
AzurRx BioPharma to Present at the Biotech Showcase 2020 Conference (January 13th)
|
06 Jan, 2020 |
|
AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer
|
03 Jan, 2020 |
